SCHEDULE: Vanguard Discloses 5.77% Stake in Organon & Co

Vanguard Portfolio Management has reported a beneficial ownership of 5.77% in Organon & Co's common stock as of June 30, 2026.

Summary

• Vanguard Portfolio Management, along with its affiliates Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, now beneficially owns 15,161,710 shares of Organon & Co common stock.
• This holding represents 5.77% of the class of securities.
• The filing is an amendment to a previous Schedule 13G filing.
• Vanguard Portfolio Management exercises sole dispositive power over these shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of Organon & Co.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive disclosure, as it indicates institutional confidence but does not provide new operational or financial performance data for Organon & Co.

Positives

• Vanguard's increased stake indicates confidence in Organon & Co's long-term prospects.
• The significant holding by a major institutional investor can provide market stability and attract further investment.

Negatives

• The filing does not contain any negative financial or operational information about Organon & Co itself, as it is a disclosure of ownership by Vanguard.

Risks

• Market volatility could impact the value of Organon & Co's stock, affecting Vanguard's investment.
• Changes in regulatory environments could impact Organon & Co's business operations and profitability.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Organon & Co. It is a disclosure of beneficial ownership by Vanguard.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Portfolio Management LLC and the following affiliates of Vanguard Portfolio Management LLC or business divisions of such affiliates: Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Portfolio Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Portfolio Management LLC, or business divisions of such subsidiaries whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that significant stake disclosures by large asset managers like Vanguard often signal a stable or positive outlook on the company's sector, in this case, likely pharmaceuticals or healthcare, and can influence investor sentiment.

Comparison to Industry Standards

• Vanguard's typical investment strategy involves acquiring significant stakes in companies across various sectors, aiming for long-term growth and diversification.
• A 5.77% stake is a substantial holding for an institutional investor, often placing them among the top shareholders and indicating a strong conviction in the company's value proposition.
• Competitors such as BlackRock and State Street Global Advisors also hold similar-sized stakes in various public companies, reflecting common practices in institutional asset management.

Stakeholder Impact

• Shareholders: May view Vanguard's increased stake as a positive signal, potentially leading to increased investor interest.
• Creditors: The stability provided by a large institutional holder could be seen as a positive indicator of the company's financial standing.
• Employees: Continued investment by major institutions can contribute to job security and company growth.

Next Steps

• Organon & Co will continue its business operations as usual.
• Vanguard Portfolio Management will monitor its investment in Organon & Co.

Key Dates

Keywords

Organon & Co, Vanguard, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Investment Management